All In Biotech

Drug Trial Radar · NCT04715646

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

84

Actual

Start

Mar 11, 2021

Primary completion

Jul 8, 2030

Study completion Jul 8, 2030

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.

Conditions

  • Epilepsy

Interventions

  • BrivaracetamDrug

    Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses. Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral Oral solution Concentration: 10 mg/ml Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
  2. Incidence of treatment-emergent serious adverse events (SAEs) during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
  3. Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the studyTime frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Ep0156 259

    Hawthorne, New York

  • Ep0156 237

    Durham, North Carolina

  • Ep0156 210

    Budapest, Hungary

  • Ep0156 247

    Budapest, Hungary

  • Ep0156 232

    Miskolc, Hungary

  • Ep0156 230

    Roma, Italy

  • Ep0156 803

    Bunkyō City, Japan

  • Ep0156 808

    Chūō, Japan

  • Ep0156 800

    Gifu, Japan

  • Ep0156 807

    Hiroshima, Japan

  • Ep0156 815

    Kodaira-shi, Japan

  • Ep0156 813

    Kōshi, Japan

  • Ep0156 806

    Kyoto, Japan

  • Ep0156 811

    Nagoya, Japan

  • Ep0156 812

    Niigata, Japan

  • Ep0156 818

    Ōbu, Japan

  • Ep0156 819

    Ōmura, Japan

  • Ep0156 817

    Osaka, Japan

  • Ep0156 805

    Sapporo, Japan

  • Ep0156 816

    Sendai, Japan

  • Ep0156 809

    Shimotsuke, Japan

  • Ep0156 814

    Shizuoka, Japan

  • Ep0156 804

    Tokyo, Japan

  • Ep0156 810

    Yokohama, Japan

  • Ep0156 802

    Yonago, Japan

  • Ep0156 223

    Aguascalientes, Mexico

  • Ep0156 609

    Culiacán, Mexico

  • Ep0156 603

    Guadalajara, Mexico

  • Ep0156 406

    Kielce, Poland

  • Ep0156 402

    Krakow, Poland

  • Ep0156 401

    Poznan, Poland

  • Ep0156 248

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.